100
Participants
Start Date
March 31, 2015
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
Darunavir
to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
Hôpital Saint Louis, Paris
ANRS, Emerging Infectious Diseases
OTHER_GOV